Available online 23 September 2022
AbstractProton pump inhibitors (PPIs) are widely prescribed and are indicated for the treatment of several GI disorders. Allergists may prescribe PPIs due to the co-incidence of gastroesophageal reflux disease (GERD) with asthma or rhinitis, or when GERD presents as chronic cough. Further, long-term high-dose PPI therapy is a recommended option for management of eosinophilic esophagitis, resulting in histologic remission in approximately 40% of patients. Here, we discuss current recommendations for PPI use, de-escalation, and their side effect profile. We review evidence supporting the epidemiologic link between use of acid-suppressant medication and subsequent development of allergic disorders.
View full text© 2022 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
留言 (0)